Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 8/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.39 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | BTK | Q06187 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21739401 | 0.87 | KMT2A (0.51) | KMT2AALDH1A1MEN1RAB9A | |
| SCHEMBL21740213 | 0.86 | MTNR1A (0.44) | KMT2AEPHX1SMYD3RAB9ABTK | |
| SCHEMBL21739921 | 0.84 | EPHX1 (0.49) | KMT2AEPHX2MEN1EPHX1RAB9A | |
| SCHEMBL21739398 | 0.84 | SETD2 (0.49) | KMT2AALDH1A1RAB9A | |
| SCHEMBL21739406 | 0.84 | SETD2 (0.49) | KMT2AALDH1A1RAB9A | |
| SCHEMBL21739405 | 0.84 | CCR8 (0.42) | KMT2AEPHX2SMYD3 | |
| SCHEMBL21739907 | 0.83 | SMYD3 (0.42) | KMT2AEPHX2ALDH1A1MEN1EPHX1 | |
| SCHEMBL21739169 | 0.83 | POLB (0.41) | KMT2AEPHX1SMYD3RAB9A | |
| SCHEMBL21739908 | 0.82 | SMYD3 (0.39) | KMT2AALDH1A1EPHX1SMYD3SMN1; SMN2 | |
| SCHEMBL21739422 | 0.81 | PTGES (0.42) | KMT2AEPHX1SMYD3BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020112872-A1 | METHODS OF TREATING WHSC1-OVEREXPRESSING CANCERS BY INHIBITING SETD2 | Epizyme, Inc. (US) | 2020-06-04 | — | — | WO | disclosed |